ACM
ASMB icon

Accent Capital Management’s Assembly Biosciences ASMB Stock Holding History

Accent Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.83K Buy
212
+70
+49% +$1.91K ﹤0.01% 276
2026
Q1 		$3.94K Buy
+142
New +$4.05K ﹤0.01% 297

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Accent Capital Management's ASMB Position: Q2 2026 in Review

Accent Capital Management increased its Assembly Biosciences (ASMB) stake by 49% in Q2 2026, buying an estimated $1.91K and bringing the position to 212 shares worth $5.83K. The position accounts for ﹤0.01% of the portfolio, ranked #276.

Accent Capital Management first reported a position in ASMB in Q1 2026 and has held it in 2 quarters since. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Accent Capital Management held 212 shares of Assembly Biosciences worth $5.83K as of Q2 2026.
  • Accent Capital Management bought 70 Assembly Biosciences shares in Q2 2026, an estimated $1.91K.
  • Assembly Biosciences made up ﹤0.01% of Accent Capital Management's portfolio in Q2 2026, its #276 holding.
  • Accent Capital Management first reported a position in Assembly Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.